China / New Leadership for Novartis Oncology
Portuguese national Isabel Afonso, a Novartis and Sandoz veteran of almost 20 years, has taken on a new role as general manager of Novartis’ highly strategic oncology franchise in China…
Global / Roche to Disentangle from Novartis, Ending Two Decades of Constraints
After 20 years, Novartis will no longer own one third of Roche’s shares after the two Swiss pharma giants agreed to a transaction worth USD 20.7 billion. While Roche touted…
China / Accelerated Approvals Down; Pfizer Drone Show; Clover Stocks Fall on HK Debut
The latest news from Chinese pharma, including a new report showing that despite the increasing number of Priority Review and Breakthrough Therapy designations awarded within China, only two Accelerated Approval…
Peptides / Technological Maturity Leading to Big Investments & Breakthroughs
With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why…
Turkey / The Future of Pharma Localization & the EU Dispute
While supporters of Turkey’s localization policy for pharmaceuticals implemented in 2016 applaud the changes it has brought, its opponents are awaiting a much-anticipated report by the World Trade Organization that…
MEA / 3 Regional Pharma Managers on their Middle East Go-To-Market Strategies
The Middle East and Africa (MEA) region is vast and is predominantly composed of emerging countries with varying levels of income and healthcare infrastructure. Here, three regional managers for pharma…
Global / Facing Adversity, Bayer Ploughs on With Big Investments
After a challenging 2020, and with more hurdles in sight, Bayer has been on an investment spree with a USD 2 billion acquisition of a San Diego-based biotech and manufacturing…
APAC / Biotech Experts Talk Regulation, Infrastructure, Funding & Talent Gaps
Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical…
LatAm / Bayer Bets Big in Costa Rica/Argentina; Mexico Drug Approvals Slow; Pfizer’s Aggressive Supply Deal Tactics
The latest from the healthcare industry in Latin America, including an alarming OECD report about the decline of well-being in the region due to Covid-19, Bayer’s USD 350 million investment…
Africa / BioNTech to Build Continent's First mRNA Manufacturing Facility
Three months after the World Bank announced a EUR 600 million loan to South Africa’s Aspen Pharmacare, the African continent has received more good news as it seeks to increase…
Italy / Biotech's Soaring R&D Spend & Post-COVID Promise
Speaking recently to PharmaBoardoom, Assobiotec’s Leonardo Vingiani introduced the key dynamics shaping the Italian biotech industry today and the issues it still has to overcome to become truly globally competitive.…
MEA / The Pharma Commercialisation Model of the Future
Amgen MEA’s Mohamed Nasser* examines the current pharma commercialisation model, posits how the entire healthcare ecosystem’s rapid and effective response to COVID-19 could be replicable in other disease areas, and…